We cover different therapeutic areas in our portfolio such as Dermatology, CNS, Specialty Care, and Rare Diseases including Metabolic, Lysosomal Storage Diseases, Ophthalmic, Neuromuscular and others.
We pride ourselves on being the leading partner for Rare Disease market access. Our diverse portfolio allows us to meet patient needs in several critical indications.
With more than 7,000 known rare diseases worldwide, the WHO defines them as debilitating lifelong diseases or disorders condition that affects fewer than or equal to 1 in 2000 persons. Today, there are more than 3M people living with a Rare Disease in the Middle East, North Africa, and Turkey (MENAT) region.
We are the leading partner for rare disease market access in the MENAT region. Our mission at Genpharm is to partner with biotech pioneers to introduce innovative cures and treatments in the region. Currently, our rare diseases portfolio includes product ranging from neuromuscular, metabolic disorders, muscular, lysosomal storage, ophthalmic, and more.
With one of our values “We Deliver On Our Promises” in mind, we are are proud to be the first company to successfully launch gene therapy in the region for rare diseases.
Central Nervous System disorders are categorized by a large group of conditions in which the brain does not function as it should, limiting health, and the ability to function.
We are proud to be partnering with global pioneers of the pharmaceutical industry to provide patients with the industry’s most effective and innovative therapies.
According to an IQVIA report, skin disorders are a significant concern for public health across the world and are ranked as the fourth leading cause of global non-fatal condition across all age categories and cultures.
At Genpharm, we thrive to provide access to MENAT patients to treatments and cures to improve public health and eliminate concerns. We have partnered with organizations to improve the quality of life of patients living with skin diseases and disorders.
With more than 7,000 known rare diseases worldwide, the WHO defines them as debilitating lifelong diseases or disorders condition that affects fewer than or equal to 1 in 2000 persons. Today, there are more than 3M people living with a Rare Disease in the Middle East, North Africa, and Turkey (MENAT) region.
We are the leading partner for rare disease market access in the MENAT region. Our mission at Genpharm is to partner with biotech pioneers to introduce innovative cures and treatments in the region. Currently, our rare diseases portfolio includes product ranging from neuromuscular, metabolic disorders, muscular, lysosomal storage, ophthalmic, and more.
With one of our values “We Deliver On Our Promises” in mind, we are are proud to be the first company to successfully launch gene therapy in the region for rare diseases.
Central Nervous System disorders are categorized by a large group of conditions in which the brain does not function as it should, limiting health, and the ability to function.
We are proud to be partnering with global pioneers of the pharmaceutical industry to provide patients with the industry’s most effective and innovative therapies.
According to an IQVIA report, skin disorders are a significant concern for public health across the world and are ranked as the fourth leading cause of global non-fatal condition across all age categories and cultures.
At Genpharm, we thrive to provide access to MENAT patients to treatments and cures to improve public health and eliminate concerns. We have partnered with organizations to improve the quality of life of patients living with skin diseases and disorders.